Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortexdopamine release

Neuropsychopharmacology

Volumn 28, Issue 1, 2003, Pages 34-44

  Balla, Andrea ^a   Sershen, Henry ^a,b   Serra, Michael ^a   Koneru, Rajeth ^a   Javitt, Daniel C ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amphetamine; Dopamine; Frontalcortex; Glutamate; NMDA receptor; Phencyclidine

Indexed keywords

AMINO ACID RECEPTOR BLOCKING AGENT; AMPHETAMINE; CENTRAL STIMULANT AGENT; DOPAMINE; HOMOVANILLIC ACID; PHENCYCLIDINE;

ANIMAL; ANIMAL BEHAVIOR; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG POTENTIATION; HYPERKINESIA; MALE; METABOLISM; MICRODIALYSIS; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PSYCHOLOGICAL ASPECT; RAT; SPRAGUE DAWLEY RAT;

AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; DRUG SYNERGISM; EXCITATORY AMINO ACID ANTAGONISTS; HOMOVANILLIC ACID; HYPERKINESIS; MALE; MICRODIALYSIS; NUCLEUS ACCUMBENS; PHENCYCLIDINE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0037209259     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/sj.npp.1300019     Document Type: Article

References (76)

1. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers Met al(1998). Increased striatal dopamine transmission inschizophrenia: confirmation in a second cohort.Am J Psychiatry155: 761-767.
2. Adams B, Moghaddam B (1998).Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitiveand locomotor effects of phencyclidine. JNeurosci18: 5545-5554.
3. Arndt S, Andreasen NC, Flaum M, Miller D, Nopoulos P (1995). A longitudinal study of symptom dimensions in schizophrenia:Prediction and patterns of change.Arch. Gen. Psychiatry52: 352-360.
4. Balla A, Hashim A, Burch S, Javitt DC, Lajtha A, Sershen H (2001a). Phencyclidine-induced dysregulation of dopamine response toamphetamine in prefrontal cortex and striatum.Neurochem Res26: 1001-1006.
5. Balla A, Koneru R, Smiley J, Sershen H, Javitt DC (2001b). Continuous phencyclidine treatment induces schizophrenia-likehyperreactivity of striatal dopamine release.Neuropsychophar-macology25: 157-164.
6. Bertolino A, Esposito G, Callicott JH, Mattay VS, Van Horn JD, Frank JAet al(2000). Specific relationship between prefrontalneuronal N-acetylaspartate and activation of the workingmemory cortical network in schizophrenia [see comments].Am J Psychiatry157: 26-233.
7. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, Bartolomeis Aet al(1997). Schizophrenia is associated withelevated amphetamine-induced synaptic dopamine concentra-tions: evidence from a novel positron emission tomographymethod.Proc Natl Acad Sci USA94: 2569-2574.
8. Carlsson A (1988). The current status of the dopamine hypothesis of schizophrenia.Neuropsychopharmacology1: 179-186.
9. Carr DB, O’Donnell P, Card JP, Sesack SR (1999). Dopamine terminals in the rat prefrontal cortex synapse on pyramidal cellsthat project to the nucleus accumbens.J Neurosci19: 11049-11060.
10. Clarke PB, Jakubovic A, Fibiger HC (1988). Anatomical analysis of the involvement of mesolimbocortical dopamine in the loco-motor stimulant actions of d-amphetamine and apomorphine.Psychopharmacology96: 511-520.
11. Cohen JD, Servan-Schreiber D (1993).A theory of dopamine function and its role in cognitive deficits in schizophrenia.Schizophr Bull19: 85-104.
12. Cosgrove J, Newell TG (1991). Recovery of neuropsychological functions during reduction in use of phencyclidine.J ClinPsychol47: 159-169.
13. Daniel DG, Weinberger DR, Jones DW, Zigun JR, Coppola R, Handel Set al(1991). The effect of amphetamine on regionalcerebral blood flow during cognitive activation in schizophrenia.J Neurosci11: 1907-1917.
14. Doherty MD, Gratton A (1997). NMDA receptors in nucleus accumbens modulate stress-induced dopamine release innucleus accumbens and ventral tegmental area.Synapse26:225-234.
15. Doherty MD, Gratton A (1999). Effects of medial prefrontal cortical injections of GABA receptor agonists and antagonists on thelocal and nucleus accumbens dopamine responses to stress.Synapse32: 288-300.
16. Druhan JP, Rajabi H, Stewart J (1996). MK-801 increase locomotor activity without elevating extracellular dopamine levels in thenucleus accumbens.Synapse24: 135-146.
17. Ehrhardt J, Sabel BA, Schroeder U (1999). Subchronically applied phencyclidine fails to disrupt prepulse inhibition in rats.EurNeuropsychopharmacol10: 69-74.
18. French ED, Vantini G (1984). Phencyclidine-induced locomotor activity in the rat is blocked by 6-hydroxydopamine lesion of the nucleusaccumbens: comparisons to other psychomotor stimu-lants.Psychopharmacology82: 83-88.
19. Gold S, Arndt S, Nopoulos P, O’Leary DS, Andreasen NC (1999).Longitudinal study of cognitive function in first-episodeand recent- onset schizophrenia.Am J Psychiatry156: 1342-1348.
20. Goldman-Rakic PS, Selemon LD (1997).Functional and anatomical aspects of prefrontal pathology in schizophrenia.Schizophr Bull23: 437-458.
21. Grace AA (1991). Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis forthe etiology of schizophrenia.Neuroscience41: 1-24.
22. Grace AA (2000).Gating of information flow within the limbic system and the pathophysiology of schizophrenia.Brain ResBrain Res Rev31: 330-341.
23. Grube BS, Bilder RM, Goldman RS (1998).Meta-analysis of symptom factors in schizophrenia.Schizophr Res31:113-120.
24. Gupta S, Andreasen NC, Arndt S, Flaum M, Hubbard WC, Ziebell S (1997). The Iowa Longitudinal Study of Recent Onset Psychosis:one-year follow-up of first episode patients.Schizophr Res23:1-13.
25. Hanania T, Johnson KM (1999). Regulation of NMDA-stimulated [14C]GABA and [3H]acetylcholine release by striatal glutamateand dopamine receptors.Brain Res844: 106-117.
26. Hata N, Nishikawa T, Umino A, Takahashi K (1990). Evidence for involvement of N-methyl-D-aspartate receptors in tonicinhibitory control of dopaminergic transmission in rat medialfrontal cortex.NeurosciLett120: 101-104.
27. Hiratsuka A, Chu TY, Distefano EW, Lin LY, Schmitz DA, Cho AK (1995).Inactivation of constitutive hepatic cytochromes P450 byphencyclidine in the rat.Drug MetabDispos23: 201-206.
28. Hondo H, Yonezawa Y, Nakahara T, Nakamura K, Hirano M, Uchimura Het al(1994). Effect of phencyclidine on dopaminerelease in the rat prefrontal cortex; anin vivomicrodialysisstudy.Brain Res633: 337-342.
29. Jansen KL (2000). A review of the nonmedical use of ketamine: use, users and consequences.J Psychoactive Drugs32: 419-433.
30. Javitt DC, Balla A, Sershen H, Lajtha A (1999). A.E. Bennett Research Award. Reversal of phencyclidine-induced effects byglycine and glycine transport inhibitors.Biol Psychiatry45: 668-679.
31. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia.Am J Psychiatry148: 1301-1308.
32. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to thedopamine hypothesis of schizophrenia.Neuropsychopharmacol-ogy20: 201-225.
33. Jentsch JD, Taylor JR, Roth RH (1998a). Subchronic phencyclidine administration increases mesolimbic dopaminergic systemresponsivity and augments stress- and psychostimulant-inducedhyperlocomotion. Neuropsychopharmacology19: 105-113.
34. Jentsch JD, Tran A, Taylor JR, Roth RH (1998b). Prefrontal cortical involvement in phencyclidine-induced activation of the meso-limbic dopamine system: behavioral and neurochemical evi-dence.Psychopharmacology (Berl)138: 89-95.
35. Kalivas PW, Duffy P, Barrow J (1989). Regulation of the mesocorticolimbic dopamine system by glutamic acid receptorsubtypes.J PharmacolExpTher251: 378-387.
36. Karreman M, Moghaddam B (1996). The prefrontal cortex regulates the basal release of dopamine in the limbic striatum:an effect mediated by ventral tegmental area.J Neurochem66:589-598.
37. Kato K, Shishido T, Ono M, Shishido K, Kobayashi M, Suzuki Het al(2000). Effects of phencyclidine on behavior and extracellularlevels of dopamine and its metabolites in neonatal ventralhippocampal damaged rats. Psychopharmacology (Berl)150:163-169.
38. Kelley AE, Throne LC (1992). NMDA receptors mediate the behavioral effects of amphetamine infused into the nucleusaccumbens.Brain Res Bull29: 247-254.
39. King D, Finlay JM (1995). Effects of selective dopamine depletion in medial prefrontal cortex on basal and evoked extracellulardopamine in neostriatum.Brain Res685: 117-128.
40. King D, Finlay JM (1997). Loss of dopamine terminals in the medial prefrontal cortex increased the ratio of DOPAC to DA intissue of the nucleus accumbens shell: role of stress.Brain Res767: 192-200.
41. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JDet al(1994). Subanesthetic effects of the noncompetitiveNMDA antagonist, ketamine, in humans.Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.Arch GenPsychiatry51: 199-214.
42. Kuczenski R, Melega WP, Cho AK, Segal DS (1997). Extracellular dopamine and amphetamine after systemic amphetamineadministration: comparison to the behavioral response.JPharmacolExpTher282: 591-596.
43. Kuczenski R, Segal D (1989). Concomitant characterization of behavioral and striatal neurotransmitter response toamphetamine usingin vivomicrodialysis.J Neurosci9: 2051-2065.
44. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995).Subanesthetic doses of ketamine stimulate psychosis in schizophrenia.Neuropsychopharmacology13: 9-19.
45. Lannes B, Micheletti G, Warter J, Kempf E, DiScala G (1991). Behavioral, pharmacological and biochemical effects of acuteand chronic administration of ketamine in the rat.NeurosciLett128: 177-181.
46. Laruelle M (1998). Imaging dopamine transmission in schizophrenia.A review and meta-analysis.Q J Nucl Med42:211-221.
47. Laruelle M, Abi-Dargham A, Gil R, Kegeles LS, Innis R (1999). Increased dopamine transmission in schizoprenia: relationshipto illness phases.Biol Psychiatry46: 56-72.
48. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D’Souza CD, Erdos Jet al(1996). Single photon emission computerizedtomography imaging of amphetamine-induced dopamine releasein drug-free schizophrenic subjects.ProcNatlAcadSci USA93:9235-9240.
49. Lewis DA, Pierri JN, Volk DW, Melchitzky DS, Woo TU (1999). Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia.Biol Psychiatry46: 616-626.
50. Lindefors N, Barati S, O’Connor WT (1997). Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontalcortex.Brain Res759: 205-212.
51. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar Det al(1996). NMDA receptor function and humancognition: the effects of ketamine in healthy volunteers.Neuropsychopharmacology14: 301-307.
52. Martinez ZA, Ellison GD, Geyer MA, Swerdlow NR (1999).Effects of sustained phencyclidine exposure on sensorimotor gating ofstartle in rats.Neuropsychopharmacology21: 28-39.
53. Mattay VS, Berman KF, Ostrem JL, Esposito G, Van Horn JD, Bigelow LB, Weinberger DR (1996). Dextroamphetamine en-hances ‘neural network-specific’ physiological signals: a positron-emission tomography rCBF study.J Neurosci16: 4816-4822.
54. McCullough LD, Salamone JD (1992). Increases in extracellular dopamine levels and locomotor activity after direct infusionof phencyclidine into the nucleus accumbens.Brain Res577:1-9.
55. Miller DW, Abercrombie ED (1996). Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release instriatum measured within vivomicrodialysis in awake rats.Brain Res Bull40: 57-62.
56. Nabeshima T, Yamada K, Yamaguchi K, Hiramatsu M, Furukawa H, Kameyama T (1983). Effect of lesions in the striatum, nucleusaccumbens and medial raphe on phencyclidine-induced stereo-typed behaviors and hyperactivity in rats. Eur J Pharmacol91:455-462.
57. Nishijima K, Kashiwa A, Hashimoto A, Iwama H, Umino A, Nishikawa T (1996). Differential effects of phencyclidine andmethamphetamine on dopamine metabolism in rat frontalcortex and striatum as revealed byin vivodialysis. Synapse22: 304-312.
58. O’Leary DS, Flaum M, Kesler ML, Flashman LA, Arndt S, Andreasen NC (2000). Cognitive correlates of the negative, disorganized, and psychotic symptom dimensions of schizo-phrenia.J Neuropsychiatry ClinNeurosci12: 4-15.
59. Ouagazzal A, Nieoullon A, Amalric M (1994). Locomotor activation induced by MK-801 in the rat: postsynaptic interactions with dopamine receptors in the ventral striatum.Eur JPharmacol251: 229-236.
60. Paxinos G, Watson C (1998).The Rat Brain in Stereotaxic Coordinates.Academic Press: New York.
61. Sams-Dodd F (1998). Effects of continuous D-amphetamine and phencyclidine administration on social behaviour, stereotypedbehaviour, and locomotor activity in rats.Neuropsychopharma-cology19: 18-25.
62. Selemon LD, Goldman-Rakic PS (1999). The reduced neuropil hypothesis: a circuit based model of schizophrenia.BiolPsychiatry45: 17-25.
63. Sesack SR, Pickel VM (1992). Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamineterminals in the nucleus accumbenssepti and on dopamineneurons in the ventral tegmental area.J Comp Neurol320: 145160.
64. Steffensen SC, Svingos AL, Pickel VM, Henriksen SJ (1998). Electrophysiological characterization of GABAergic neurons inthe ventral tegmental area.J Neurosci18: 8003-8015.
65. Szeszko PR, Bilder RM, Dunlop JA, Walder DJ, Lieberman JA (1999). Longitudinal assessment of methylphenidate effects onoral word production and symptoms in first-episode schizophre-nia at acute and stabilized phases.Biol Psychiatry45: 680-686.
66. Taber MT, Baker GB, Fibiger HC (1996). Glutamate receptor agonists decrease extracellular dopamine in the rat nucleusaccumbensin vivo.Synapse24: 165-172.
67. Takahata R, Moghaddam B (1998). Glutamatergic regulation of basal and stimulus-activated dopamine release in the prefrontalcortex.J Neurochem71: 1443-1449.
68. Takahata R, Moghaddam B (2000). Target-specific glutamatergic regulation of dopamine neurons in the ventral tegmental area.JNeurochem75: 1775-1778.
69. Thompson TL, Moss RL (1995).In vivostimulated dopamine release in the nucleus accumbens: modulation by the prefrontalcortex.Brain Res686: 93-98.
70. Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC (2000). Ketamine-induced deficits in auditory and visualcontext-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.Arch GenPsychiatry57: 1139-1147.
71. Walberg CB, McCarron MM, Schulze BN (1983). Quantitation of phencyclidine in serum by enzyme immunoassay: results in 405patients.J Anal Toxicol7: 106-110.
72. Wang C, Showalter VM, Hillman GR, Johnson KM (1999). Chronic phencyclidine increases NMDA receptor NR1 subunit mRNA inrat forebrain.J Neurosci Res55: 762-769.
73. Weinberger DR, Lipska BK (1995). Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground.Schizophr Res16: 87-110.
74. Weir E (2000). Raves: a review of the culture, the drugs and the prevention of harm [see comments].Cmaj162: 1843-1848.
75. Wolf ME, Xue CJ, White FJ, Dahlin SL (1994). MK-801 does not prevent acute stimulatory effects of amphetamine or cocaine onlocomotor activity or extracellular dopamine levels in ratnucleus accumbens.Brain Res666: 223-231.
76. Yonezawa Y, Kuroki T, Kawahara T, Tashiro N, Uchimura H (1998). Involvement of gamma-aminobutyric acid neurotrans-mission in phencyclidine-induced dopamine release in themedial prefrontal cortex.Eur J Pharmacol341: 45-56.